Emcure Pharmaceuticals (NSE:EMCURE) COGS-to-Revenue : 0.42 (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Emcure Pharmaceuticals COGS-to-Revenue?

Emcure Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2025 was ₹8,921 Mil. Its Revenue for the three months ended in Mar. 2025 was ₹21,162 Mil.

Emcure Pharmaceuticals's COGS to Revenue for the three months ended in Mar. 2025 was 0.42.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Emcure Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2025 was 57.84%.

Emcure Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Emcure Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emcure Pharmaceuticals COGS-to-Revenue Chart

Emcure Pharmaceuticals Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Mar25

COGS-to-Revenue

0.38

0.39

0.38

0.37

0.40

Emcure Pharmaceuticals Quarterly Data
	Mar21	Mar22	Mar23	Sep23	Dec23	Mar24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial				0.37	0.38	0.39	0.40	0.42

Emcure Pharmaceuticals COGS-to-Revenue Calculation

Emcure Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	31466.03	/	78959.97
	=	0.40

Emcure Pharmaceuticals's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	8921.1	/	21162.45
	=	0.42

Emcure Pharmaceuticals (NSE:EMCURE) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Emcure Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	8921.1 / 21162.45
	=	57.84 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Emcure Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Emcure Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Emcure Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emcure Pharmaceuticals Ltd (NSE:EMCURE) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

544210:India

Address

Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Hinjawadi, MH, IND, 411057

Website

https://www.emcure.com

Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics.

Emcure Pharmaceuticals Headlines

No Headlines